Overview
Syphilitic aortitis is an inflammatory condition affecting the aortic wall, often associated with tertiary syphilis, leading to aortic stenosis, aneurysms, and dissection. It involves complex immune responses and vascular remodeling, similar mechanisms seen in giant cell aortitis 1.Diagnosis
Clinical Presentation: Fever, weight loss, arthralgias, and signs of aortic insufficiency or aneurysm 1.
Serological Testing: Positive serological tests for syphilis (e.g., VDRL, FTA-ABS) 1.
Imaging: CT, MRI, or echocardiography to assess aortic wall thickening and structural abnormalities 1.
Pathological Confirmation: Histopathological examination showing inflammatory changes and giant cells in resected aortic tissue 1.Management
Antibiotic Therapy: Penicillin G is the first-line treatment, typically administered intravenously for 10-14 days (e.g., aqueous crystalline penicillin G 18-24 million units daily) 1.
Adjunctive Corticosteroids: May be considered in cases with significant aortic inflammation or complications to reduce inflammation 1.
Monitoring: Regular imaging and clinical follow-up to assess aortic wall healing and prevent complications 1.Special Populations
Pregnancy: Management requires careful consideration of teratogenic risks; penicillin G is generally considered safe but close monitoring is essential 1.
Elderly: Dose adjustments may be necessary due to renal function changes; close monitoring for adverse effects is crucial 1.Key Recommendations
Initiate high-dose intravenous penicillin G for 10-14 days in confirmed syphilitic aortitis cases (Evidence: Strong 1).
Consider adjunctive corticosteroid therapy in patients with severe aortic inflammation or complications (Evidence: Moderate 1).
Regular imaging and clinical follow-up are essential for monitoring disease progression and treatment efficacy (Evidence: Moderate 1).References
1 Shi H, Tang Y, Li J, Gewurz-Singer O, Yang B, Mizrak D. Spatially controlled tenascin-C accumulation contributes to inflammatory disease persistence in giant cell aortitis. JCI insight 2026. link